|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9189 USD | -6.23% |
|
-10.79% | +79.82% |
| 04-19 | YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023 | CI |
| 04-18 | YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment | MT |
YS Biopharma Co., Ltd. reported earnings results for the half year ended September 30, 2023. For the half year, the company reported sales was CNY 273.09 million compared to CNY 399.53 million a year ago. Net loss was CNY 174.52 million compared to CNY 83.21 million a year ago.
Basic loss per share from continuing operations was CNY 1.88 compared to CNY 0.18 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +79.82% | 173M | |
| -1.62% | 89.22B | |
| +2.24% | 40.49B | |
| -12.97% | 32.79B | |
| +62.36% | 26.23B | |
| -20.71% | 14.52B | |
| -7.31% | 13.09B | |
| -12.64% | 11.5B | |
| -42.60% | 11.6B | |
| +4.27% | 8.82B |
YS BIOPHARMA CO., LTD. 
